GSK Vaccine Study

A phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/AS01b vaccine, adminstered intramuscularly according to either a two dose (0, 4 weeks) or a three dose (0, 4, 28 weeks) schedule in ART-naive, HIV-1 infected persons aged 18-55 years. (Closed for enrollment).